ReviewSeminars in respiratory and critical care medicine2019
Acute Pulmonary Exacerbations in Cystic Fibrosis.
Review in Seminars in respiratory and critical care medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Use of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024Pooled it
- C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022Trial
- A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.American journal of respiratory and critical care medicine · 2021Trial
- A prospective randomised controlled mixed-methods pilot study of home monitoring in adults with cystic fibrosis.Therapeutic advances in respiratory diseaseTrial
- Anti-inflammatory and phosphorylation effects of CFTR modulator triple therapy in cystic fibrosis.iScience · 2026Article
- Pilot and Feasibility Study of an Individualized Telehealth Exercise Program for People with Cystic Fibrosis.Journal of functional morphology and kinesiology · 2026Article
- Pulmonary hypertension in pediatric patients with cystic fibrosis during acute pulmonary exacerbations: prevalence and associated factors.BMC pulmonary medicine · 2026Article
- Acute exposure to fine ambient particulate matter and pulmonary exacerbations in cystic fibrosis: A case-crossover study.Atmospheric Environment: X · 2026Article
- Inflammation and oxidative stress in the sputum of patients with cystic fibrosis: correlations with lung function, aerobic fitness, and morbidity.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2026Observational
- Pseudomonas aeruginosa infection exacerbates elastase induced lung damage: characterisation of a novel murine two-hit model of pulmonary infection.Respiratory research · 2025Article
- Viral Infection Correlates with a Better Clinical Outcome than Pulmonary Exacerbation of Bacterial Origin in Paediatric Patients with Cystic Fibrosis.Pathogens (Basel, Switzerland) · 2025Article
- Species turnover within cystic fibrosis lung microbiota is indicative of acute pulmonary exacerbation onset.Microbiome · 2025Article
- State-of-the-Art Review: Transformative Changes in the Care of People With Cystic Fibrosis: Implications for Infectious Diseases Specialists.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Review
- The Significance of Density Measurement and the Modified Bhalla and Reiff Scores in Predicting Exacerbations and Hospital Admissions in Cystic Fibrosis Patients.Medicina (Kaunas, Lithuania) · 2025Article
- Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis.Pediatric pulmonology · 2025Article
- Robust identification of environmental exposures and community characteristics predictive of rapid lung disease progression.The Science of the total environment · 2024Article
- Therapeutic Interventions forJournal of clinical medicine · 2024Review
- Treatment of Psychological Symptoms in Patients with Cystic Fibrosis.Journal of clinical medicine · 2024Review
- Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review.BMJ open respiratory research · 2024Article
- Predicting return of lung function after a pulmonary exacerbation using the cystic fibrosis respiratory symptom diary-chronic respiratory infection symptom scale.BMC pulmonary medicine · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
With the improving survival of cystic fibrosis (CF) patients and the advent of highly effective cystic fibrosis transmembrane conductance regulator therapy, the clinical spectrum of this complex multisystem disease continues to evolve. One of the most important clinical events for patients with CF in the course of this disease is an acute pulmonary exacerbation. Clinical and microbial epidemiology studies of CF pulmonary exacerbations continue to provide important insight into the disease course, prognosis, and complications. This work has now led to a number of large scale clinical trials with the goal of improving the treatment paradigm for CF pulmonary exacerbation. The primary goal of this review is to provide a summary of the pathophysiology, the clinical epidemiology, microbial epidemiology, outcome and the treatment of CF pulmonary exacerbation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.